BrainStorm Cell Therapeutics Inc.:
NurOwn® autologous cell therapy platform for neurodegenerative diseases. Lead candidate for ALS, Ph2 evaluated 60 ALS pts w favorable safety/tolerability. Ph3 currently enrolling 200 pts across 6 US centers; top-line data expected in mid-2020. Second indication is progressive MS - IND accepted Dec 2018.
Central Nervous System, Rare Disease
100MM - 500MM
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by